Due to the fact that Human papillomavirus has been named one of six cancer causing viruses, scientists are continually working to research new treatments. While being the culprit for almost all cases of cervical cancer in women, HPV has also been linked to causing anogenital cancer as well as some head and neck cancers. At this point, various strains of HPV have been identified to be more high risk than others, which is why research for treatments has been focused on specific strains. Strains such as HPV’s 16, 18, 31, 45 are the most high risk strains for cervical cancer as they account for roughly 80% of cases. Incredibly enough, vaccines have been developed to target the HPV16 and HPV18 strains and they are available now to protect against cancer development from these high risk strains. If a new treatment were to be created, the HPV31 or HPV45 strains should be targeted next in order to continue to eliminate high risk cancer causing strains of HPV. If a vaccine were to be created for HPV31 or HPV45, it would likely need to be administered to children ages 11-12 in accordance with guidelines for the already developed HPV vaccines. Additionally, it would be ideal for vaccines to be developed that would account for all high risk strains of HPV, but given a cost/benefit analysis, the HPV31 and HPV45 would be of upmost importance at this time.